Sirigen II Limited
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
6
Ending by 2030
Oct 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 30, 2027The maintenance fee for Novel Reagents for Directed Biomarker Signal Amplification (US 10,365,285) comes due Jan 30, 2027. Unpaid by Jul 30, 2027, it lapses early.
- 1 fee due Mar 22, 2027The maintenance fee for Novel Reagents for Directed Biomarker Signal Amplification (US 9,139,869) comes due Mar 22, 2027. Unpaid by Sep 22, 2027, it lapses early.
- 1 fee due Apr 29, 2027The maintenance fee for Novel Reagents for Directed Biomarker Signal Amplification (US 10,458,989) comes due Apr 29, 2027. Unpaid by Oct 29, 2027, it lapses early.
- 1 fee due May 19, 2027The maintenance fee for Novel Reagents for Directed Biomarker Signal Amplification (US 10,481,161) comes due May 19, 2027. Unpaid by Nov 19, 2027, it lapses early.
- 1 fee due Jul 16, 2027The maintenance fee for Reagents for directed biomarker signal amplification (US 11,874,278) comes due Jul 16, 2027. Unpaid by Jan 18, 2028, it lapses early.
- 1 fee due Aug 13, 2027The maintenance fee for Reagents for directed biomarker signal amplification (US 11,899,018) comes due Aug 13, 2027. Unpaid by Feb 14, 2028, it lapses early.
- 1 fee due Nov 5, 2027The maintenance fee for Novel Reagents for Directed Biomarker Signal Amplification (US 10,641,775) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,107,818 | Fluorescent methods and materials for directed biomarker signal amplification In force · From the USPTO record | In force | From the USPTO record | |
| US 10,126,302 | Fluorescent methods and materials for directed biomarker signal amplification In force · From the USPTO record | In force | From the USPTO record | |
| US 11,639,937 | Fluorescent Methods and Materials for Directed Biomarker Signal Amplification In force · Low confidence | In force | Low confidence | |
| US 12,366,578 | Fluorescent methods and materials for directed biomarker signal amplification In force · From the USPTO record | In force | From the USPTO record | |
| US 11,209,438 | Fluorescent methods and materials for directed biomarker signal amplification In force · From the USPTO record | In force | From the USPTO record | |
| US 12,366,577 | Fluorescent methods and materials for directed biomarker signal amplification In force · From the USPTO record | In force | From the USPTO record | |
| US 8,362,193 | Novel Reagents for Directed Biomarker Signal Amplification In force · Low confidence | In force | Low confidence | |
| US 8,455,613 | Novel Reagents for Directed Biomarker Signal Amplification In force · Low confidence | In force | Low confidence | |
| US 8,575,303 | Novel Reagents for Directed Biomarker Signal Amplification In force · Medium confidence | In force | Medium confidence | |
| US 9,139,869 | Novel Reagents for Directed Biomarker Signal Amplification In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 28: 1 patent in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 no status recorded